1. This article discusses the mechanisms of progressive fibrosis in interstitial lung diseases (ILDs) related to connective tissue diseases (CTDs).
2. It reviews current evidence on the diagnosis, clinical course, and therapeutic management of progressive-fibrosing interstitial lung diseases.
3. The article also examines the efficacy and safety of various treatments for CTD-related progressive fibrosing interstitial lung diseases, such as nintedanib, pirfenidone, cyclophosphamide, tocilizumab, imatinib mesylate, and BIBF 1120.
This article is a comprehensive review of the mechanisms of progressive fibrosis in interstitial lung diseases (ILDs) related to connective tissue diseases (CTDs). The authors provide an overview of current evidence on the diagnosis, clinical course, and therapeutic management of progressive-fibrosing interstitial lung diseases. They also examine the efficacy and safety of various treatments for CTD-related progressive fibrosing interstitial lung diseases.
The article is well written and provides a thorough review of the literature on this topic. The authors have included a wide range of sources from peer-reviewed journals as well as conference presentations and posters. This indicates that they have conducted a thorough search for relevant literature on this topic. Furthermore, all sources are properly cited throughout the text which adds to its credibility.
The authors have presented both sides of the argument fairly by providing evidence for both positive and negative outcomes associated with different treatments for CTD-related progressive fibrosing interstitial lung disease. They have also discussed potential risks associated with these treatments which adds to its trustworthiness.
In conclusion, this article is reliable and trustworthy due to its comprehensive coverage of available evidence on this topic as well as its balanced presentation of both sides of the argument.